贵州百灵(002424) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥1,332,744,270.05, representing a 22.09% increase compared to ¥1,091,626,153.16 in the same period last year[11] - Net profit attributable to shareholders decreased by 44.00% to ¥51,695,103.14 from ¥92,306,394.78 year-on-year[11] - Basic and diluted earnings per share fell by 42.86% to ¥0.04 from ¥0.07 in the same quarter last year[11] - The net profit for the first quarter of 2024 was CNY 51,074,838.51, a decrease of 44.5% compared to CNY 91,853,787.63 in the same period last year[30] - The total profit for the first quarter was CNY 64,666,186.76, down from CNY 125,645,269.48, reflecting a decline of 48.5% year-over-year[30] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥-254,664,208.38, a decline of 340.05% compared to ¥-57,871,366.46 in the previous year[11] - Cash and cash equivalents at the end of the period totaled ¥286,905,027.85, down from ¥471,054,001.52 at the end of the previous period[46] - The company’s cash and cash equivalents were reported at CNY 1,200,000,000.00, indicating a stable liquidity position[27] - Cash inflow from financing activities was ¥541,065,828.18, compared to ¥476,702,269.62 in the prior period, indicating a 13.5% increase[46] - Cash flow from financing activities generated a net amount of CNY 152,285,614.18, showing an increase in financing scale compared to the previous year[36] Assets and Liabilities - Total assets increased by 6.05% to ¥7,793,968,923.01 from ¥7,349,081,335.53 at the end of the previous year[11] - The total liabilities increased to ¥4,300,273,919.08 from ¥3,821,833,000.42, reflecting a growth of 12.5%[45] - Current liabilities increased to CNY 4,045,112,372.70, compared to CNY 3,516,562,997.56, marking a growth of approximately 15.03%[26] - Short-term borrowings rose to CNY 1,598,493,527.89 from CNY 1,436,017,612.52, representing an increase of about 11.29%[26] - Long-term borrowings decreased to CNY 149,713,888.90 from CNY 199,776,527.78, showing a decline of about 25.06%[26] Equity and Shareholder Information - The company's equity attributable to shareholders decreased by 0.94% to ¥3,479,423,576.57 from ¥3,512,356,643.12 at the end of the previous year[11] - The company reported a total equity of CNY 3,748,856,550.31, reflecting an increase from the previous period[27] - The number of ordinary shareholders at the end of the reporting period was 106,426, with the largest shareholder holding 17.39% of the shares[36] Research and Development - Research and development expenses decreased by 81.54% to ¥3,020,082.42 compared to ¥16,358,969.36 in the same period last year[19] - Ongoing R&D investments in new technologies are expected to reach CNY 200 million in 2024, focusing on innovative pharmaceutical solutions[27] - The company incurred research and development expenses of ¥3,020,082.42, significantly lower than ¥16,358,969.36 in the previous period[45] Market Strategy and Future Outlook - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2025[27] - The company aims to expand its market presence and enhance product development in the upcoming quarters, focusing on innovation and strategic partnerships[37] - The company’s revenue for the first quarter of 2024 is projected to grow by 10% year-over-year, driven by new product launches[27] Accounts Receivable and Inventory - Accounts receivable increased by 38.05% to ¥2,389,302,456.37, primarily due to an increase in sales on credit[19] - Accounts receivable increased to CNY 2,389,302,456.37 from CNY 1,730,811,639.87, representing a rise of 38.0% year-over-year[39] - Inventory at the end of the first quarter was CNY 1,218,788,365.67, compared to CNY 1,163,683,187.16 at the beginning of the year, reflecting a growth of 4.7%[39] Investment Income - The company reported a significant decrease in investment income, down 34.18% to ¥-5,833,183.59 from ¥-4,347,137.40 year-on-year[19] - The company's interest income and other income totaled CNY 4,627,661.00, while investment losses amounted to CNY -5,833,183.59, indicating a challenging investment environment[30] - The company received government subsidies amounting to ¥2,279,424.81 during the reporting period[15]